Cozad Asset Management Inc. Acquires Shares of 12,372 AstraZeneca plc (AZN)

Cozad Asset Management Inc. acquired a new stake in AstraZeneca plc (NYSE:AZN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 12,372 shares of the company’s stock, valued at approximately $434,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bessemer Group Inc. raised its stake in shares of AstraZeneca by 64.3% in the second quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock valued at $163,000 after acquiring an additional 1,820 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in AstraZeneca in the second quarter valued at $175,000. Tiverton Asset Management LLC acquired a new stake in AstraZeneca in the second quarter valued at $178,000. Gilman Hill Asset Management LLC acquired a new stake in AstraZeneca in the second quarter valued at $205,000. Finally, Clarius Group LLC acquired a new stake in AstraZeneca in the second quarter valued at $213,000. Institutional investors and hedge funds own 15.99% of the company’s stock.

A number of analysts have weighed in on the company. ValuEngine upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, July 28th. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, July 16th. BMO Capital Markets restated a “buy” rating and issued a $41.00 price target on shares of AstraZeneca in a research note on Friday, May 25th. Morningstar restated a “hold” rating on shares of AstraZeneca in a research note on Tuesday, June 12th. Finally, Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $38.94.

AstraZeneca stock opened at $37.45 on Friday. AstraZeneca plc has a 1-year low of $31.99 and a 1-year high of $39.76. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.54 and a current ratio of 0.72. The firm has a market capitalization of $95.97 billion, a price-to-earnings ratio of 10.55, a price-to-earnings-growth ratio of 2.01 and a beta of 0.60.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 26th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.38. The company had revenue of $5.16 billion for the quarter, compared to analyst estimates of $5.09 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.87 earnings per share. analysts anticipate that AstraZeneca plc will post 1.68 earnings per share for the current fiscal year.

The company also recently disclosed a semiannual dividend, which was paid on Monday, September 10th. Shareholders of record on Friday, August 10th were issued a dividend of $0.45 per share. This represents a dividend yield of 2.35%. The ex-dividend date of this dividend was Thursday, August 9th. AstraZeneca’s payout ratio is 20.56%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Book Value Per Share – BVPS

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply